American society of addiction medicine pcss-SUD treatment - the american society of addiction medicine (ASAM) will implement the providers clinical support system - substance use disorder treatment…
Active Project Grant Awarded Last action
- Award ID
- H79TI088516
- Recipient
-
American Society Of Addiction Medicine Inc. UEI U8HJKRULEFH8
- Awarding agency
-
SAMHSA Division of Grants Management
Substance Abuse and Mental Health Services Administration, Department of Health and Human Services
- Obligated
- $2,999,542
Award facts
- Assistance listing
- 93.490 Center for Substance Abuse Treatment Projects of Regional and National Significance
- Completion date 4% complete
- Funding agency
- SAMHSA Center for Substance Abuse Treatment Substance Abuse and Mental Health Services Administration, Department of Health and Human Services
- Place of performance
- North Bethesda, MD 20852, USA
Award details come from USAspending.gov.
About this award
The Substance Abuse and Mental Health Services Administration (SAMHSA) Center for Substance Abuse Treatment awarded the American Society of Addiction Medicine Inc. $2,999,542 on September 30, 2026, under the Center for Substance Abuse Treatment Projects of Regional and National Significance program (CFDA 93.490) to implement the Providers Clinical Support System – Substance Use Disorder Treatment (PCSS-SUD Treatment).
PCSS-SUD Treatment is a national training and technical assistance program designed to strengthen healthcare and counseling professionals' capacity to deliver evidence-based substance use disorder prevention, treatment, and recovery services across the United States. The program will provide universal, targeted, and intensive training and technical assistance through a coordinated national platform offering live and on-demand education, ECHO sessions, podcasts, microlearning videos, implementation academies, learning communities, mentoring, consultation, office hours, and digital resources. Over the three-year performance period, PCSS-SUD Treatment will deliver universal training and technical assistance to at least 115,000 healthcare and counseling professionals, targeted assistance to at least 20,000 professionals, and intensive assistance to at least 500 professionals. The program will serve professionals working with youth and adolescents, adults, rural communities, individuals with co-occurring conditions, veterans, service members and their families, and justice-involved populations. The program will emphasize adoption of evidence-based and integrated practices, including appropriate use of FDA-approved medications for substance use disorders.
Performance of work occurs in North Bethesda, Maryland, with a period of performance from September 30, 2026, through September 29, 2029.
Description
American society of addiction medicine pcss-SUD treatment - the american society of addiction medicine (ASAM) will implement the providers clinical support system - substance use disorder treatment (pcss-SUD treatment), a national training and technical assistance (TTA) program designed to strengthen the capacity of healthcare and counseling professionals to deliver evidence-based substance use disorder (SUD) prevention, treatment, and recovery services across the united states. Through education, mentoring, consultation, and technical assistance, pcss-SUD treatment will expand access to high-quality SUD care, strengthen workforce capacity, and improve outcomes for individuals, families, communities, and systems affected by suds. The program will support healthcare and counseling professionals serving youth/adolescents, adults, rural communities, individuals with CO-occurring conditions, veterans, service members and their families, justice-involved populations, and other high-need populations. Building on ASAM's established pcss-maud infrastructure, the program will provide universal, targeted, and intensive TTA through a coordinated national platform offering live and on-demand education, echo sessions, podcasts, microlearning videos, implementation academies, learning communities, mentoring, consultation, office hours, and digital resources. The program will leverage multidisciplinary partnerships, innovative transfer strategies, and implementation support to promote adoption of evidence-based and integrated SUD prevention, treatment, and recovery practices, including the appropriate use of FDA-approved medications for substance use disorders (MSUD). Over the three-year program period, pcss-SUD treatment will provide universal TTA to at least 115,000 healthcare and counseling professionals, targeted TTA to at least 20,000 professionals, and intensive TTA to at least 500 professionals. The program will maintain a centralized national resource platform, recruit at least 70 multidisciplinary mentors, support 19 community health centers and fqhcs through learning communities, 1,200 learners through implementation academies, and provide consultation, mentoring, and technical assistance to at least 780 professionals nationwide. Through these activities, the program will strengthen clinical competencies, increase implementation of evidence-based practices, expand access to treatment and recovery services, and strengthen organizational capacity to deliver integrated SUD care. The program will pursue five goals: (1) strengthen workforce capacity to deliver evidence-based integrated SUD prevention, treatment, and recovery-support services; (2) increase access to a coordinated national infrastructure for evidence-based SUD training, consultation, mentoring, and technical assistance; (3) increase adoption of evidence-based and integrated SUD prevention, treatment, and recovery-support practices; (4) improve workforce capacity to address the challenges faced by high-need populations; and (5) strengthen the workforce's ability to respond to emerging substance use and behavioral health challenges. Key objectives include providing universal, targeted, and intensive TTA nationwide; maintaining a centralized platform for education, consultation, mentoring, and technical assistance; training at least 60,000 healthcare professionals in the appropriate use and integration of FDA-approved MSUD; increasing the percentage of professionals who report implementation of evidence-based practice changes to 85%; providing specialized TTA to at least 45,000 professionals serving high-need populations; and annually identifying emerging substance use and behavioral health threats and developing timely educational and technical assistance responses. Program performance will be monitored through gpra performance measures, continuous quality improvement processes, and ongoing evaluation activities to ensure effectiveness, accountability, and alignment with samhsa strategic priorities.
Quick answers
Who received award H79TI088516?
H79TI088516 was awarded to American Society Of Addiction Medicine Inc. by SAMHSA Division of Grants Management (Substance Abuse and Mental Health Services Administration) on September 30, 2026.
How much is award H79TI088516 worth?
$2,999,542 has been obligated on H79TI088516.
Which agency awarded H79TI088516?
SAMHSA Division of Grants Management (Substance Abuse and Mental Health Services Administration) awarded H79TI088516, with funding from SAMHSA Center for Substance Abuse Treatment (Substance Abuse and Mental Health Services Administration).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award